Metagenomi, Inc. Common Stock
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a MGX research report →
Range $7 – $22
Price Chart
About the company
Metagenomi, Inc. operates as a biotechnology company focused on gene editing, committed to developing therapeutic solutions for patients. The company utilizes a distinctive genome editing toolkit, sourced from metagenomics, for its development efforts within the United States.
- CEO
- Jian Irish
- IPO
- 2024
- Employees
- 113
- HQ
- Emeryville, CA, US
Get TickerSpark's AI analysis on MGX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $38.78M
- P/E
- -0.41
- PEG
- 0.07
- P/S
- 2.86
- P/B
- 0.34
- EV/EBITDA
- -0.42
- Div Yield
- 0.00%
- Gross Margin
- 74.29%
- Op Margin
- -741.58%
- Net Margin
- -689.20%
- ROE
- -63.65%
- ROIC
- -65.88%
Latest fiscal year · YoY change
- Revenue
- $25.21M-51.8%
- Gross Profit
- $19.89M-62.0%
- Op Income
- $-96,013,000
- Net Income
- $-87,868,000-12.6%
- EPS
- $-2.36-12.9%
- OCF Growth
- +18.5%
- FCF Growth
- +20.3%
- 52W High
- $3.95
- 52W Low
- $1.01
- 50D MA
- $1.18
- 200D MA
- $1.37
- Beta
- 0.70
- RSI (14)
- 34
- Avg Volume
- 155.47K
No earnings-call transcripts are available for MGX yet.
- Free Float
- 67.6%
- Shares Outstanding
- 37.65M
- Float Shares
- 25.44M
of shares held by institutions
47 13F filers
Buy/sell ratio 0.67. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Vanguard Group Inc | 1.27M | ▲ 28.74K |
| Vanguard Capital Management LLC | 1.08M | ▲ 19.76K |
| Renaissance Technologies LLC | 742.40K | ▼ 45.50K |
| Sozo Ventures Gp Ii, L.P. | 581.58K | 0 |
| Catalio Capital Management, LP | 528.99K | 0 |
| Peapod Lane Capital LLC | 525.02K | ▲ 8.26K |
| Two Sigma Investments, LP | 513.70K | ▲ 16.93K |
| Bridgeway Capital Management, LLC | 400.30K | ▲ 4.50K |
| Wells Fargo & Company/Mn | 379.51K | ▲ 177.37K |
| Geode Capital Management, LLC | 288.67K | ▼ 69.53K |
| Pura Vida Investments, LLC | 264.39K | 0 |
| Blackrock, Inc. | 257.63K | ▲ 27.50K |
Held by 26 ETFs
Biggest fund positions in MGX by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Sep 9, 26 | Reid Laurence | buy | 117 |
| Sep 9, 26 | Reid Laurence | buy | 19,883 |
| Sep 8, 26 | Wein Matthew | sell | 358 |
| Sep 8, 26 | Irish Jian | sell | 2,140 |
| Sep 8, 26 | Wapnick Pamela | sell | 1,911 |
| Jun 9, 26 | Reid Laurence | other | 17,400 |
| Jun 9, 26 | Dere Willard H | other | 21,000 |
| Jun 9, 26 | BJERKHOLT ERIC | other | 21,000 |
| Jun 9, 26 | Eckhardt Juergen | other | 21,000 |
| Jun 5, 26 | Wapnick Pamela | sell | 2,884 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our MGX coverage
Recent articles, reports, and earnings notes.
No research on MGX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate MGX report →Reviewing Metagenomi (NASDAQ:MGX) and BioMarin Pharmaceutical (NASDAQ:BMRN)
defenseworld.net · Sep 30
Metagenomi Therapeutics, Inc. to Present at the Wells Fargo 21st Annual Healthcare Conference
globenewswire.com · Sep 1
Did Metagenomi Therapeutics, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
prnewswire.com · Aug 25
MGX Resources Limited (MTGRY) Q4 2026 Earnings Call Prepared Remarks Transcript
seekingalpha.com · Aug 20
Metagenomi Therapeutics (MGX) Reports Q2 Loss, Lags Revenue Estimates
zacks.com · Aug 10
MGX Resources Limited (MTGRY) Q4 2026 Earnings Call Transcript
seekingalpha.com · Jul 20
Prolynx Names Simon Harnest as Chief Financial Officer and Amer Mirza, PhD, as Chief Scientific Officer as It Advances Multi-Program Obesity and Metabolic Disease Portfolio
globenewswire.com · Jul 15
Did Metagenomi Therapeutics, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
gurufocus.com · Jun 5
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.